# US 2024/0254238 A1 · Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254238 A1
- Document ID: US20240254238A1
- Status: Published application
- Kind: A1
- Application number: 18/562,921
- Filed: 2022-05-19
- Published: 2024-08-01
- Earliest claimed: 2021-05-26
- Applicants: Oxford Biotherapeutics Ltd
- Inventors: Christian ROHLFF
- Web page: https://patentgrep.com/patent/US20240254238A1

## CPC

- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6831: {Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for increasing the anti-tumor immune response in a patient suffering from cancer, a method for the treatment or prophylaxis of cancer, and a method for enhancing the effectiveness of an inhibitor of PD1/PD-L1 interactions. Also provided are pharmaceutical combinations comprising (a) antibodies, or antigen-binding portions thereof, directed against CD205, and (b) a PD1/PD-L1 checkpoint inhibitor.

## Claims

### Claim 1

A method for the treatment or prophylaxis of cancer comprising administering to a patient in need thereof a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells and a therapeutically effective amount of a composition comprising a checkpoint modulator.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the checkpoint modulator is directed towards a checkpoint protein selected from the group comprising PD1, PD-L1, PD-L2, CTLA-4, ICOS, TIGIT, CD28, TMIGD2, CD137, CD137L, CD27, OX40, OX40L, LAG3, VISTA, GITR, DNAM-1, CD96, 2B4, TIM-3, CEACAM, CRTAM, SLAMF6, Galectin-9, CD48, CD155, GITRL, CD40, CD40L, CD70, HVEM, B7-H7, B7-H3, B7-H4, ICOSL, CD80, CD86, BTLA, CD160, LIGHT, Adenosine A2a receptor, SIRP alpha, DC-SIGN, CD200R, DR3, TL1A, CD200, BTN2A1, CD47, IDO, TDO.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or claim 2, wherein the checkpoint modulator is a PD1 or PD-L1 inhibitor, preferably PD1.

### Claim 4

A method for enhancing the effectiveness of an inhibitor of PD-1/PD-L1 in a patient identified as being in need thereof, said method comprising administering to said patient (a) a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells and (b) a composition comprising an inhibitor of PD-1/PD-L1 interactions.

### Claim 5 (depends on 3, 4)

The method according to claim 3 or claim 4, wherein the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells and the composition comprising the inhibitor of PD-1/PD-L1 are administered simultaneously, separately or sequentially, preferably sequentially.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein the checkpoint modulator is an antibody.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said antibody is an anti PD1 or PD-L1 antibody

### Claim 8 (depends on 7)

The method according to claim 7, wherein said anti-PD-1 antibody is Nivolumab (MDX-1 106, Opdivo; Bristol-Myers Squibb), Pembrolizumab (MK-3475, Keytruda, lambrolizumab, BMS-936558; Merck), Cemiplimab (REGN-2810, Libtayo; Regeneron), Dostarlimab (TSR-042, Tesaro, Inc.), EH12.2H7 (ENUM-388D4, BioLegend, catalog no. 329902), Balstilimab (Agenus Inc).

### Claim 9 (depends on 7)

The method according to claim 7, wherein said anti-PD-L1 antibody is Avelumab (Bavencio; EMD Serono, Pfizer), Durvalumab (Imfinzi, AstraZeneca), BMS-936559, Atezolizumab (Tecentriq, Genentech).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1 to 9, wherein the patient is administered at least 1 cycle, at least 2 cycles, at least 3 cycles, at least 4 cycles or at least 5 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint modulator.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the patient is administered 1 to 5 cycles, 2 to 4 cycles or 2 to 3 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint modulator.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11 wherein the patient is subsequently administered at least 1, at least 2, at least 3, at least 4 or at least 5 or more cycles of the checkpoint modulator.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the checkpoint modulator is administered between 7 days and 12 weeks after administration of the antibody or antigen binding fragment thereof which modulates the population of CD205+ immune modulatory cells, preferably between 7 days and 10 weeks, or 7 days and 8 weeks, or 7 days and 6 weeks, or 7 days and 4 weeks, or 7 and 21 days or 10 and 19 days, or 12 and 16 days, or 14 and 16 days, or 19 and 28 days, more preferably 20 and 25 days, most preferably 21 and 24 days.

### Claim 14

A method for increasing the anti-tumor immune response in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells.

### Claim 15 (depends on 14)

The method according to claim 14 wherein the anti-tumor immune response is an immune cell mediated tumour specific response.

### Claim 16 (depends on 14, 15)

The method according to claim 14 or claim 15, wherein the anti-tumor immune response is a NK cell mediated tumour specific response.

### Claim 17 (depends on 14, 15)

The method according to claim 14 or 15, wherein the anti-tumor immune response is a T-cell mediated tumour specific response.

### Claim 18

A method for increasing the number of T-cells in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof which modulates the population of CD205+ immune modulatory cells.

### Claim 19

A method for reducing size of a tumor in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof which modulates the population of CD205+ immune modulatory cells.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the tumor is a metastatic tumour.

### Claim 21 (depends on 20)

The method of claim 20, wherein the metastatic tumor is in the lung or the liver.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21 wherein the population of CD205+ immune modulatory cells are CD8+.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the population of CD205+ CD8+ immune modulatory cells are depleted.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21 wherein the immune modulatory cells are pDCs and/or mDCs

### Claim 25 (depends on 24)

The method according to claim 24 wherein the populations of pDCs and/or mDCs are increased.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to claim any one of claims 1 to 21 wherein the population of CD205+ immune modulatory cells are CD4+.

### Claim 27 (depends on 26)

The method according to claim 26 wherein the population of CD205+ CD4+ immune modulatory cells are depleted.

### Claim 28 (depends on 22, 23, 26, 27)

The method according to any one of claims 22 to 23 or 26 to 27 wherein the immune modulatory cells are T-Reg cells.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method according to any one of claims 1 to 28, wherein the immune modulatory cells are immune inhibitory cells.

### Claim 30 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method according to any one of claims 17 to 29, wherein the T-cells are CD8+ T-cells.

### Claim 31 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method according to any one of claims 17 to 29, wherein the T-cells are CD4+ T-cells.

### Claim 32 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claims 18 to 31, wherein said patient is simultaneously, separately, sequentially or subsequently administered a cancer vaccine.

### Claim 33 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claims 18 to 31, wherein said patient is simultaneously, separately, sequentially or subsequently administered a bispecific antibody.

### Claim 34 (depends on 33)

The method according to claim 33 wherein said bispecific antibody is a T-cell engager (BiTE).

### Claim 35 (depends on 33, 34)

The method according to claim 33 or claim 34, wherein said bispecific antibody comprises a first binding domain which binds to CD3.

### Claim 36 (depends on 33, 34, 35)

The method according to any one of claims 33 to 35 wherein said bispecific antibody comprises a second binding domain which binds to tumor specific antigen.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method according to any one of claims 1 to 36, wherein said patient is refractory to, or whose cancer has progressed on, at least one chemotherapy.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any one of claims 1 to 37, wherein said patient is refractory to checkpoint modulator therapy.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method according to any one of claims 1 to 38, wherein said patient is ineligible for checkpoint modulator therapy.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the checkpoint modulator therapy is PD1 therapy.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method according to any one of claims 1 to 40, wherein said cancer is PDL1 negative or low.

### Claim 42 (depends on 41)

The method according to claim 41, wherein said patient has a cancer having less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1% PD-L1 expression.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 1 to 42 wherein said cancer is MSI stable.

### Claim 44

The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD8+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 45

The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD4+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 46

The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the pDCs and/or mDCs in a blood sample previously isolated from said patient are CD205+.

### Claim 47

The method according to any preceding claim, wherein the antibody or antigen binding portion thereof binds to CD205.

### Claim 48

The method according to any preceding claim, wherein the antibody or antigen binding portion thereof binds to CD205 and comprises:
a heavy chain variable region comprising:
iii) a first vhCDR comprising SEQ ID NO: 5;
ii) a second vhCDR comprising SEQ ID NO: 6;
iii) a third vhCDR comprising SEQ ID NO: 7; and
a light chain variable region comprising:
iii) a first vlCDR comprising SEQ ID NO: 8;
ii) a second vlCDR comprising SEQ ID NO: 9;
iii) a third vlCDR comprising SEQ ID NO: 10;
wherein optionally any one or more of the above SEQ ID Nos independently comprise one or two amino acid substitutions, preferably conservative substitutions.

### Claim 49

The method according to any preceding claim, wherein the antibody or an antigen-binding portion thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 2.

### Claim 50

The method according to any preceding claim, wherein the antibody which binds to CD205 comprises
(iii) a heavy chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 100; and
(ii) a light chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 101.

### Claim 51

The method according to any preceding claim, wherein the antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety.

### Claim 52 (depends on 51)

The method according to claim 51, wherein said moiety is a drug.

### Claim 53 (depends on 52)

The method according to claim 52, wherein said drug is selected from the group consisting of a maytansinoid, a dolastatin, a hemiasterlin, an auristatin, a trichothecene, a calicheamicin, a duocarmycin, a bacterial immunotoxin, a pyranoindoizinoquinoline, a camptothecin, an anthracycline, an antheamycin, a thienoindole, an amatoxin, CC1065 or taxol and derivatives thereof.

### Claim 54 (depends on 53)

The method according to claim 53, wherein said drug is a maytansinoid selected from the group consisting of DM4 and DM1, preferably DM4.

### Claim 55

The method according to any preceding claim, wherein said cancer is a CD205 positive cancer.

### Claim 56

The method according to any preceding claim, wherein said cancer is selected from the group consisting of gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastroesophageal junction cancer, pancreatic cancer, breast cancer, colorectal cancer, skin cancer, thyroid cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, leukaemia, preferably acute myeloid leukaemia or chronic lymphocytic leukaemia, myeloma, preferably multiple myeloma and lymphoma, preferably diffuse large B-cell lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt's Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the cancer is selected from the group comprising: gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastroesophageal junction cancer, cancer breast cancer, bladder cancer, and renal cancer.

### Claim 58

The method according to any preceding claim, wherein the patient is a human.

### Claim 59

A pharmaceutical combination comprising:
iii) an anti CD205 antibody or antigen binding portion thereof, said antibody comprising:
a heavy chain variable region comprising:
iii) a first vhCDR comprising SEQ ID NO: 5;
ii) a second vhCDR comprising SEQ ID NO: 6;
iii) a third vhCDR comprising SEQ ID NO: 7; and
a light chain variable region comprising:
iii) a first vlCDR comprising SEQ ID NO: 8;
ii) a second vlCDR comprising SEQ ID NO: 9;
iii) a third vlCDR comprising SEQ ID NO: 10; and
b) a checkpoint modulator.

### Claim 60 (depends on 59)

The pharmaceutical combination according to claim 59, wherein the pharmaceutical combination is in the form of a combined preparation for simultaneous, separate or sequential use, preferably sequential.

### Claim 61 (depends on 59, 60)

The pharmaceutical combination according to claim 59 or claim 60, wherein the checkpoint modulator is a PD1/PD-L1 inhibitor, preferably the PD1/PD-L1 inhibitor is an antibody.

### Claim 62 (depends on 61)

The pharmaceutical combination according to claim 61, wherein the PD1/PD-L1 inhibitor is selected from the list comprising Nivolumab (MDX-1 106, Opdivo; Bristol-Myers Squibb), Pembrolizumab (MK-3475, Keytruda, lambrolizumab, BMS-936558; Merck), Dostarlimab (TSR-042 Tesaro, Inc.), Cemiplimab (REGN-2810, Libtayo; Regeneron), EH12.2H7 (BioLegend, catalog no. 329902), Balstilimab (Agenus Inc), Avelumab (Bavencio; EMD Serono, Pfizer), Durvalumab (Imfinzi, AstraZeneca), BMS-936559, Atezolizumab (Tecentriq, Genentech), or an equivalent thereto.

### Claim 63 (depends on 59, 60, 61, 62)

The pharmaceutical combination according to any one of claims 59 to 62, wherein the anti CD205 antibody or an antigen-binding portion thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 2.

### Claim 64 (depends on 59, 60, 61, 62, 63)

The pharmaceutical combination according to any one of claims 59 to 63, wherein antibody which binds to CD205 comprises;
(i) a heavy chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 100; and
(ii) a light chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 101.

### Claim 65 (depends on 59, 60, 61, 62, 63, 64)

The pharmaceutical combination according to any one of claims 59 to 64, wherein the antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety.

### Claim 66 (depends on 65)

The pharmaceutical combination according to claim 65, wherein said moiety is a drug.

### Claim 67 (depends on 66)

The pharmaceutical combination according to claim 66, wherein said drug is selected from the group consisting of a maytansinoid, a dolastatin, a hemiasterlin, an auristatin, a trichothecene, a calicheamicin, a duocarmycin, a bacterial immunotoxin, a pyranoindoizinoquinoline, a camptothecin, an anthracycline, an antheamycin, a thienoindole, an amatoxin, CC1065 or taxol and derivatives thereof.

### Claim 68 (depends on 67)

The pharmaceutical combination according to claim 67, wherein said drug is a maytansinoid selected from the group consisting of DM4 and DM1, preferably DM4.

### Claim 69 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The pharmaceutical combination according to any one of claims 59 to 68, comprising at least one pharmaceutically acceptable diluent, excipient or carrier.

### Claim 70

An antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells for use in increasing the anti-tumor immune response in a patient suffering from cancer.

### Claim 71 (depends on 70)

The antibody or antigen binding portion thereof for use according to claim 70 wherein the anti-tumor immune response is an immune cell mediated tumour specific response.

### Claim 72 (depends on 70, 71)

The antibody or antigen binding portion thereof for use according to claim 70 or 71, wherein the anti-tumor immune response is a NK cell mediated tumour specific response.

### Claim 73 (depends on 70, 71, 72)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 72, wherein the anti-tumor immune response is a T-cell mediated tumour specific response.

### Claim 74

An antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells for use in increasing the number of T-cells in a patient suffering from cancer.

### Claim 75 (depends on 70, 71, 72, 73, 74)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 74 wherein the population of CD205+ immune modulatory cells are CD8+.

### Claim 76 (depends on 75)

The antibody or antigen binding portion thereof for use according to claim 75 wherein the population of CD205+ CD8+ immune modulatory cells are depleted.

### Claim 77 (depends on 70, 71, 72, 73, 74)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 74 wherein the immune modulatory cells are pDCs and/or mDCs

### Claim 78 (depends on 77)

The antibody or antigen binding portion thereof for use according to claim 77 wherein the populations of pDCs and/or mDCs are increased.

### Claim 79 (depends on 70, 71, 72, 73, 74)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 74 wherein the population of CD205+ immune modulatory cells are CD4+.

### Claim 80 (depends on 79)

The antibody or antigen binding portion thereof for use according to claim 79 wherein the population of CD205+ CD4+ immune modulatory cells are depleted.

### Claim 81 (depends on 75, 76, 79, 80)

The antibody or antigen binding portion thereof for use according to any one of claims 75 to 76 or 79 to 80 wherein the immune modulatory cells are T-Reg cells.

### Claim 82 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 81, wherein the immune modulatory cells are immune inhibitory cells.

### Claim 83 (depends on 73, 82)

The antibody or antigen binding portion thereof for use according to any one of claim 73 to claim 82 wherein the T-cells are CD8+ T-cells.

### Claim 84 (depends on 73, 82)

The antibody or antigen binding portion thereof for use according to any one of claim 73 to claim 82, wherein the T-cells are CD4+ T-cells.

### Claim 85 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 84, wherein said patient is simultaneously, separately, sequentially or subsequently administered a cancer vaccine.

### Claim 86 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 84, wherein said patient is simultaneously, separately, sequentially or subsequently administered a bispecific antibody.

### Claim 87 (depends on 86)

The antibody or antigen binding portion thereof for use according to claim 86 wherein said bispecific antibody is a T-cell engager (BITE).

### Claim 88 (depends on 82, 86)

The antibody or antigen binding portion thereof for use according to claim 86 or claim 82, wherein said bispecific antibody comprises a first binding domain which binds to CD3.

### Claim 89 (depends on 86, 87, 88)

The antibody or antigen binding portion thereof for use according to any one of claims 86 to 88 wherein said bispecific antibody comprises a second binding domain which binds to tumor specific antigen.

### Claim 90 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 89, wherein said patient is refractory to, or whose cancer has progressed on at least one chemotherapy.

### Claim 91 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 90, wherein said patient is refractory to checkpoint modulator therapy.

### Claim 92 (depends on 91)

The antibody or antigen binding portion thereof for use according to claim 91, wherein the checkpoint modulator therapy is PD1 inhibitor therapy.

### Claim 93 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 92, wherein said cancer is PDL1 negative or low.

### Claim 94 (depends on 93)

The antibody or antigen binding portion thereof for use according to claim 93, wherein said cancer has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1% PD-L1 expression.

### Claim 95 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 94, wherein said cancer is MSI stable.

### Claim 96 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 95, wherein at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD8+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 97 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 95, wherein at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD4+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 98 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The antibody or antigen binding portion thereof for use according to any one of claims 70 to 95, wherein at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the pDCs and/or mDCs in a blood sample previously isolated from said patient are CD205+.

### Claim 99

A pharmaceutical combination for use in the treatment or prophylaxis of cancer, said combination comprising; an antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells; and a composition comprising a checkpoint modulator.

### Claim 100 (depends on 99)

The pharmaceutical combination for use according to claim 99, wherein the checkpoint modulator is directed towards a checkpoint protein selected from the group comprising PD1, PD-L1, PD-L2, CTLA-4, ICOS, TIGIT, CD28, TMIGD2, CD137, CD137L, CD27, OX40, OX40L, LAG3, VISTA, GITR, DNAM-1, CD96, 2B4, TIM-3, CEACAM, CRTAM, SLAMF6, Galectin-9, CD48, CD155, GITRL, CD40, CD40L, CD70, HVEM, B7-H7, B7-H3, B7-H4, ICOSL, CD80, CD86, BTLA, CD160, LIGHT, Adenosine A2a receptor, SIRP alpha, DC-SIGN, CD200R, DR3, TL1A, CD200, BTN2A1, CD47, IDO, TDO.

### Claim 101 (depends on 99, 100)

The pharmaceutical combination for use according to claim 99 or 100, wherein the checkpoint modulator is a PD1 or PD-L1 inhibitor, preferably PD1.

### Claim 102

A pharmaceutical combination for use in enhancing the effectiveness of an inhibitor of PD-1/PD-L1 interactions in a patient, said combination comprising; an antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells; and a composition comprising an inhibitor of PD1/PD-L1 interactions.

### Claim 103 (depends on 99, 100, 101, 102)

The pharmaceutical combination for use according to any one of claims 99 to 102 wherein the pharmaceutical combination is in the form of a combined preparation for simultaneous, separate or sequential use, preferably sequential.

### Claim 104 (depends on 99, 100, 101, 102, 103)

The pharmaceutical combination for use according to any one of claims 99 to 103, wherein the population of CD205+ immune modulatory cells are CD8+.

### Claim 105 (depends on 104)

The pharmaceutical combination for use according to claim 104, wherein the population of CD205+ CD8+ immune modulatory cells are depleted.

### Claim 106 (depends on 99, 100, 101, 102, 103)

The pharmaceutical combination for use according to any one of claims 99 to 103, wherein the immune modulatory cells are pDCs and/or mDCs.

### Claim 107 (depends on 106)

The pharmaceutical combination for use according to claim 106 wherein the populations of pDCs and/or mDCs are increased.

### Claim 108 (depends on 99, 100, 101, 102, 103)

The pharmaceutical combination for use according to any one of claims 99 to 103, wherein the population of CD205+ immune modulatory cells are CD4+.

### Claim 109 (depends on 108)

The pharmaceutical combination for use according to claim 108 wherein the population of CD205+ CD4+ immune modulatory cells are depleted.

### Claim 110 (depends on 104, 105, 108, 109)

The pharmaceutical combination for use according to any one of claims 104 to 105 or 108 to 109 wherein the immune modulatory cells are T-Reg cells.

### Claim 111 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The pharmaceutical combination for use according to any one of claims 99 to 110, wherein the immune modulatory cells are immune inhibitory cells.

### Claim 112 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The pharmaceutical combination for use according to any one of claims 99 to 111, wherein said patient is simultaneously, separately, sequentially or subsequently administered a cancer vaccine.

### Claim 113 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The pharmaceutical combination for use to any one of claims 99 to 111, wherein said patient is simultaneously, separately, sequentially or subsequently administered a bispecific antibody.

### Claim 114 (depends on 113)

The pharmaceutical combination for use according to claim 113 wherein said bispecific antibody is a T-cell engager (BiTE).

### Claim 115 (depends on 113, 114)

The pharmaceutical combination for use according to claim 113 or claim 114, wherein said bispecific antibody comprises a first binding domain which binds to CD3.

### Claim 116 (depends on 113, 114)

The pharmaceutical combination for use according to any one of claims 113 to 114 wherein said bispecific antibody comprises a second binding domain which binds to tumor specific antigen.

### Claim 117 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The pharmaceutical combination for use according to any one of claims 99 to 116, wherein the patient is administered at least 1 cycle, at least 2 cycles, at least 3 cycles, at least 4 cycles or at least 5 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint modulator.

### Claim 118 (depends on 117)

The pharmaceutical combination for use according to claim 117 wherein the patient is administered 1 to 5 cycles, 2 to 4 cycles or 2 to 3 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint modulator.

### Claim 119 (depends on 117, 118)

The pharmaceutical combination for use of claim 117 or 118 wherein the patient is subsequently administered at least 1, at least 2, at least 3, at least 4 or at least 5 or more cycles of the checkpoint modulator.

### Claim 120 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The pharmaceutical combination for use according to any one of claims 99 to 119, wherein the checkpoint modulator is administered between 7 days and 12 weeks after administration of the antibody or antigen binding portion thereof which binds to CD205, preferably between 7 days and 10 weeks, or 7 days and 8 weeks, or 7 days and 6 weeks, or 7 days and 4 weeks, or 7 and 21 days or 10 and 19 days, or 12 and 16 days, or 14 and 16 days, or 19 and 28 days, more preferably 20 and 25 days, most preferably 21 and 24 days.

### Claim 121 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The pharmaceutical combination for use according to any one of claims 99 to 120, wherein said patient is refractory to, or whose cancer has progressed on, at least one chemotherapy.

### Claim 122 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The pharmaceutical combination for use according to any one of claims 99 to 121, wherein said patient is refractory to checkpoint modulator therapy.

### Claim 123 (depends on 122)

The pharmaceutical combination for use according to claim 122, wherein the checkpoint modulator therapy is PD1 inhibitor therapy.

### Claim 124 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The pharmaceutical combination for use according to any one of claims 99 to 123, wherein said cancer is PDL1 negative or low.

### Claim 125 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The pharmaceutical combination for use according to any one of claims 99 to 124, wherein said cancer is MSI stable.

### Claim 126 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The pharmaceutical combination for use according to any one of claims 99 to 125 wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD8+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 127 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The pharmaceutical combination for use according to any one of claims 99 to 125 wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD4+ cells in a blood sample previously isolated from said patient are CD205+.

### Claim 128 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The pharmaceutical combination for use according to any one of claims 99 to 125 wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the pDCs and/or mDCs in a blood sample previously isolated from said patient are CD205+.

### Claim 129 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 128, wherein the antibody or antigen binding portion thereof binds to CD205.

### Claim 130 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 129, wherein the antibody or antigen binding portion thereof which binds to CD205 comprises:
a heavy chain variable region comprising:
i) a first vhCDR comprising SEQ ID NO: 5;
ii) a second vhCDR comprising SEQ ID NO: 6; and
iii) a third vhCDR comprising SEQ ID NO: 7; and
a light chain variable region comprising:
i) a first vlCDR comprising SEQ ID NO: 8;
ii) a second vlCDR comprising SEQ ID NO: 9; and
iii) a third vlCDR comprising SEQ ID NO: 10
wherein optionally any one or more of the above SEQ ID NOs independently comprise one or two amino acid substitutions, preferably conservative substitutions.

### Claim 131 (depends on 70, 130)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claim 70 to claim 130, wherein the antibody or an antigen-binding portion thereof which binds to CD205 comprises a heavy chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO: 2.

### Claim 132 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The antibody or pharmaceutical combination for use according to any one of claims 70 to 131, wherein antibody which binds to CD205 comprises;
(i) a heavy chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 100; and
(ii) a light chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 101.

### Claim 133 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 132, wherein the antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety.

### Claim 134 (depends on 133)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to claim 133, wherein said moiety is a drug.

### Claim 135 (depends on 134)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to claim 134, wherein said drug is selected from the group consisting of a maytansinoid, a dolastatin, a hemiasterlin, an auristatin, a trichothecene, a calicheamicin, a duocarmycin, a bacterial immunotoxin, a pyranoindoizinoquinoline, a camptothecin, an anthracycline, an antheamycin, a thienoindole, an amatoxin, CC1065 or taxol and derivatives thereof.

### Claim 136 (depends on 135)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to claim 135, wherein said drug is a maytansinoid selected from the group consisting of DM4 and DM1, preferably DM4.

### Claim 137 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The pharmaceutical combination for use according to any one of claims 99 to 136, wherein the checkpoint modulator is an antibody.

### Claim 138 (depends on 137)

The pharmaceutical combination for use according to claim 137 wherein said antibody is an anti PD1 or PD-L1 antibody.

### Claim 139 (depends on 138)

The pharmaceutical combination for use according to claim 138, wherein said anti-PD-1 antibody is Nivolumab (MDX-1 106, Opdivo; Bristol-Myers Squibb), Pembrolizumab (MK-3475, Keytruda, lambrolizumab, BMS-936558; Merck), Dostarlimab (TSR-042 Tesaro, Inc.), Cemiplimab (REGN2810 Regeneron Pharmaceuticals), EH12.2H7 (BioLegend, catalog no. 329902), Balstilimab (Agenus Inc).

### Claim 140 (depends on 138)

The pharmaceutical combination for use according to claim 138, wherein said anti-PD-L1 antibody is Avelumab (Bavencio; EMD Serono, Pfizer), Durvalumab (Imfinzi, AstraZeneca), BMS-936559, Atezolizumab (Tecentriq, Genentech).

### Claim 141 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 140, wherein said cancer is a CD205 positive cancer.

### Claim 142 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 141, wherein said cancer is selected from the group consisting of gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastroesophageal junction cancer, pancreatic cancer, breast cancer, colorectal cancer, skin cancer, thyroid cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, leukaemia, preferably acute myeloid leukaemia or chronic lymphocytic leukaemia, myeloma, preferably multiple myeloma and lymphoma, preferably diffuse large B-cell lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt's Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

### Claim 143 (depends on 142)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to claim 142, wherein the cancer is selected from the group comprising: gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastroesophageal junction cancer, breast cancer, bladder cancer, and renal cancer.

### Claim 144 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The antibody or antigen binding portion thereof or pharmaceutical combination for use according to any one of claims 70 to 143, wherein the patient is a human.

### Claim 145

A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
identifying a patient wherein at least 20% of the CD8+ cells in a blood sample previously isolated from said patient are CD205+ and administering a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.

### Claim 146

An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
a. determining the percentage of CD8+ cells in a blood sample previously isolated from said patient that are CD205+ cells; and
b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ cells in the blood sample CD205+.

### Claim 147 (depends on 146)

The in vitro method of claim 146, further comprising the step of administering to said patient a therapeutically effective amount of said antibody or antigen binding fragment thereof which binds to CD205.

### Claim 148

A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
a. obtaining a blood sample from said patient,
b. identifying whether at least 20% of the CD8+ cells in the blood sample are CD205+.

### Claim 149 (depends on 148)

The method according to claim 148, further comprising the step of administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ cells in the blood sample are CD205+.

### Claim 150 (depends on 145, 146, 147, 148, 149)

The method according to any one of claims 145 to 149 wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD8+ cells are CD205+.

### Claim 151

A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
identifying a patient wherein at least 20% of the CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.

### Claim 152

An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
a. determining the percentage of CD4+ cells in a blood sample previously isolated from said patient that are CD205+ cells; and
b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD4+ cells in the blood sample CD205+.

### Claim 153 (depends on 152)

The in vitro method of claim 152, further comprising the step of administering to said patient a therapeutically effective amount of said antibody or antigen binding fragment thereof which binds to CD205.

### Claim 154

A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
a. obtaining a blood sample from said patient,
b. identifying whether at least 20% of the CD4+ cells in the blood sample are CD205+.

### Claim 155 (depends on 154)

The method according to claim 154, further comprising the step of administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD4+ cells in the blood sample are CD205+.

### Claim 156 (depends on 151, 152, 153, 154, 155)

The method according to any one of claims 151 to 155 wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD4+ cells are CD205+.

### Claim 157

A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
identifying a patient wherein at least 20% of the CD8+ and CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.

### Claim 158

An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
a. determining the percentage of CD8+ and CD4+ cells in a blood sample previously isolated from said patient that are CD205+ cells; and
b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ and CD4+ cells in the blood sample CD205+.

### Claim 159 (depends on 158)

The in vitro method of claim 158, further comprising the step of administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.

### Claim 160

A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
a. obtaining a blood sample from said patient,
b. identifying whether at least 20% of the CD8+ and CD4+ cells in the blood sample are CD205+.

### Claim 161 (depends on 160)

The method according to claim 160, further comprising the step of administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ and CD4+ cells in the blood sample are CD205+.

### Claim 162 (depends on 157, 158, 159, 160, 161)

The method according to any one of claims 157 to 161 wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD8+ and CD4+ cells are CD205+.

### Claim 163

A method for the treatment or prophylaxis of cancer comprising, identifying a patient wherein at least 20% of the CD8+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.

### Claim 164 (depends on 163)

The method according to claim 163, wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD8+ cells are CD205+.

### Claim 165

A method for the treatment or prophylaxis of cancer comprising, identifying a patient wherein at least 20% of the CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.

### Claim 166 (depends on 165)

The method according to claim 165, wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD4+ cells are CD205+.

### Claim 167

A method for the treatment or prophylaxis of cancer comprising identifying a patient wherein at least 20% of the CD8+ cells and CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.

### Claim 168 (depends on 167)

The method according to claim 167, wherein at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of said patient's CD8+ and CD4+ cells are CD205+.

### Claim 169

A treatment method comprising:
(a) calculating the percentage of CD4+ and/or CD8+ cells that are CD205+ in a blood sample previously isolated from a patient diagnosed with cancer to identify the patient as having a responder phenotype; and
(b) administering a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205 to the patient having a responder phenotype.

### Claim 170 (depends on 169)

The treatment method according to claim 169, wherein at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of the CD4+ and/or CD8+ cells in the blood sample previously isolated from a patient diagnosed with cancer are CD205+ positive.

### Claim 171 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170)

The method according to any one of claims 145 to 170, comprising the further step of subsequently administering to said patient a checkpoint modulator.

### Claim 172 (depends on 171)

The method according to claim 171, wherein the checkpoint modulator is directed towards a checkpoint protein selected from the group comprising PD1, PD-L1, PD-L2, CTLA-4, ICOS, TIGIT, CD28, TMIGD2, CD137, CD137L, CD27, OX40, OX40L, LAG3, VISTA, GITR, DNAM-1, CD96, 2B4, TIM-3, CEACAM, CRTAM, SLAMF6, Galectin-9, CD48, CD155, GITRL, CD40, CD40L, CD70, HVEM, B7-H7, B7-H3, B7-H4, ICOSL, CD80, CD86, BTLA, CD160, LIGHT, Adenosine A2a receptor, SIRP alpha, DC-SIGN, CD200R, DR3, TL1A, CD200, BTN2A1, CD47, IDO, TDO.

### Claim 173 (depends on 172)

The method according to claim 172, wherein the checkpoint modulator is an antibody.

### Claim 174 (depends on 173)

The method according to claim 173, wherein said antibody is a PD1 or PD-L1 inhibitor, preferably PD1.

### Claim 175 (depends on 174)

The method according to claim 174, wherein said anti-PD-1 antibody is Nivolumab (MDX-1 106, Opdivo; Bristol-Myers Squibb), Pembrolizumab (MK-3475, Keytruda, lambrolizumab, BMS-936558; Merck), Cemiplimab (REGN-2810, Libtayo; Regeneron), Dostarlimab (TSR-042, Tesaro, Inc.), EH12.2H7 (ENUM-388D4, BioLegend, catalog no. 329902), Balstilimab (Agenus Inc).

### Claim 176 (depends on 174)

The method according to claim 174, wherein said anti-PD-L1 antibody is Avelumab (Bavencio; EMD Serono, Pfizer), Durvalumab (Imfinzi, AstraZeneca), BMS-936559, Atezolizumab (Tecentriq, Genentech).

### Claim 177 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The method according to any one of claims 145 to 176, wherein said patient is simultaneously, separately, sequentially or subsequently administered a cancer vaccine.

### Claim 178 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The method according to any one of claims 145 to 176, wherein said patient is simultaneously, separately, sequentially or subsequently administered a bispecific antibody.

### Claim 179 (depends on 178)

The method according to claim 178 wherein said bispecific antibody is a T-cell engager (BiTE).

### Claim 180 (depends on 178, 179)

The method according to claim 178 or claim 179, wherein said bispecific antibody comprises a first binding domain which binds to CD3.

### Claim 181 (depends on 178, 179, 180)

The method according to any one of claims 178 to 180 wherein said bispecific antibody comprises a second binding domain which binds to tumor specific antigen.

### Claim 182 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The method according to any one of claims 145 to 181, wherein said patient is refractory to, or whose cancer has progressed on, at least one previously line of chemotherapy.

### Claim 183 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The method according to any one of claims 145 to 182, wherein said patient is refractory to checkpoint modulator therapy.

### Claim 184 (depends on 183)

The method according to claim 183, wherein the checkpoint modulator therapy is PD1 therapy.

### Claim 185 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184)

The method according to claim any one of claims 145 to 184, wherein said cancer is PDL1 negative or low.

### Claim 186 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method according to any one of claims 145 to 185 wherein said cancer is MSI stable.

### Claim 187 (depends on 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186)

The method according to any one of claims 145 to 186, wherein the patient is administered at least 1 cycle, at least 2 cycles, at least 3 cycles, at least 4 cycles or at least 5 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint inhibitor.

### Claim 188 (depends on 187)

The method according to claim 187 wherein the patient is administered 1 to 5 cycles, 2 to 4 cycles or 2 to 3 cycles of the antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells prior to administration of the checkpoint modulator.

### Claim 189 (depends on 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The method according to any one of claims 171 to 188 wherein the patient is administered at least 1, at least 2, at least 3, at least 4 or at least 5 or more cycles of the checkpoint modulator.

### Claim 190 (depends on 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The method according to any one of claims 171 to 189, wherein the checkpoint modulator is administered between 7 days and 12 weeks after administration of the antibody or antigen binding portion thereof which binds to CD205, preferably between 7 days and 10 weeks, or 7 days and 8 weeks, or 7 days and 6 weeks, or 7 days and 4 weeks, or 7 and 21 days or 10 and 19 days, or 12 and 16 days, or 14 and 16 days, or 19 and 28 days, more preferably 20 and 25 days, most preferably 21 and 24 days.
